Phase II Study of Gemcitabine, 5-Fluorouracil, and Leucovorin in Patients With Pancreatic Cancer

The primary goal of this phase II study was to determine the efficacy of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) plus 5-fluorouracil in patients with pancreatic cancer. Eligibility criteria included nonresectable locally advanced or metastatic pancreatic adenocarcinoma and measurable disease. Gemcitabine at 1,000 mg/m2 and leucovorin at 20 mg/m2 were administered Intravenously 30 minutes before 5-fluorouracil 600 mg/m2,...